Schistosome resistance to praziquantel: Fact or artifact?
Praziquantel is the current drug of choice for human schistosomiasis. Recent reports from laboratory and field studies concerning reduced praziquantel efficacy against Schistosoma mansoni have generated some controversy. The prevailing question is whether the emergence of strains of schistosome resistant to praziquantel is a fact, or an artifact resulting from erroneous field or laboratory experimentation. In this article, Padraic Fallon, Liang-feng Tao, Magdi Ismail and James Bennett examine the available evidence for schistosome resistance to praziquantel. Contributory factors to the schistosomicidal activity of praziquantel, which may interfere with evaluation of drug efficacy or resistance, are also considered.
Fallon
P G
PG
Department of Pathology, University of Cambridge. Tennis Court Road, Cambride, UK. pgf@mole.bio.cam.uk
Tao
L F
LF
Ismail
M M
MM
Bennett
J L
JL